Sildenafil Tablet, Film Coated
Product Images NDC 71205-088

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71205-088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Sildenafil Citrate (Image 01)

Chemical structure of Sildenafil, showing the molecular arrangement with labeled atoms and functional groups consistent with the active ingredient Sildenafil.*

FDA Label Image

Figure1 (Image 02)

A line graph comparing systolic blood pressure (mmHg) over 24 hours post-dose for Sildenafil 100 mg and placebo. The x-axis represents time post-dose in hours, and the y-axis represents changes in systolic blood pressure. Two lines with different markers indicate measurements for Sildenafil and placebo groups.*

FDA Label Image

Figure2 (Image 03)

A line graph comparing changes in systolic blood pressure (SBP) over time postdose (hours) for two treatments: Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. The y-axis shows change in SBP in mm Hg, while the x-axis represents time postdose up to 8 hours. Two colored lines represent the different treatments, illustrating their effect on SBP over time.*

FDA Label Image

Figure3 (Image 04)

Line graph showing the change in systolic blood pressure (mmHg) over time postdose (hours) comparing two treatments: Doxazosin with Placebo and Doxazosin with Sildenafil 50 mg. The graph depicts distinct trends in blood pressure changes across an 8-hour period postdose for each treatment group.*

FDA Label Image

Figure4 (Image 05)

A line graph comparing blood pressure changes (mmHg) over time (hours) after dosing with Doxazosin plus Sildenafil 100 mg versus Doxazosin plus Placebo. The graph shows two trend lines, indicating variations in blood pressure reduction within an 8-hour period after oral administration.*

FDA Label Image

Figure5 (Image 06)

A line graph depicting plasma concentrations of Sildenafil over a 24-hour period post-dose. The x-axis represents time in hours after dosing, and the y-axis shows plasma concentrations in ng/mL. Data points connected by lines represent the concentration profile of a commercial Sildenafil tablet.*

FDA Label Image

Figure6 (Image 07)

Two bar graphs depicting the effect of Sildenafil Citrate and Placebo on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis shows the percentage of patients at endpoint for each baseline score. Different bars correspond to scores 0 through 5 for both Sildenafil Citrate and Placebo groups, illustrating patient response distributions.*

FDA Label Image

Figure7 (Image 08)

A bar graph showing the percentage of patients reporting improvement across four treatment groups: Placebo, Sildenafil 25 mg, Sildenafil 50 mg, and Sildenafil 100 mg. The percentage of improvement increases with the dosage of Sildenafil, ranging from 24% for placebo to 82% for Sildenafil 100 mg. The graph includes sample sizes for each group and indicates an overall treatment significance with p < 0.0001.*

FDA Label Image

71205-088-20 (Image 11)

Label for Sildenafil 100 mg film-coated tablets by Proficient Rx LP. The package contains 20 tablets. Tablets are described as white to off-white, modified oval-shaped, convex with debossed markings. Manufactured in Croatia by Pliva Hrvatska d.o.o. Storage instructions and multiple product identifiers, including NDC 71205-088-20, are shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.